^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lymphoma

    Related cancers:
    1d
    A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=80, Recruiting, City of Hope Medical Center | Trial completion date: Jan 2026 --> Jan 2029 | Trial primary completion date: Jan 2026 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    IL4 (Interleukin 4)
    1d
    Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    Rituxan (rituximab) • bortezomib • alisertib (MLN8237) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    1d
    Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    1d
    SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1/2, N=48, Recruiting, University of California, San Diego | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    Rituxan (rituximab)
    1d
    Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy (clinicaltrials.gov)
    P2, N=41, Not yet recruiting, Fondazione Italiana Linfomi - ETS
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Columvi (glofitamab-gxbm)
    1d
    CD45BE-HSPC + CART-45 Cells (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, University of Pennsylvania
    New P1 trial
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • BCL6 (B-cell CLL/lymphoma 6) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    1d
    BV-ALLO: Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=14, Completed, University of Cologne | Recruiting --> Completed | N=21 --> 14
    Trial completion • Enrollment change
    |
    Adcetris (brentuximab vedotin)
    1d
    A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=41, Recruiting, Jennifer Crombie, MD | Active, not recruiting --> Recruiting
    Enrollment open
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive • CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    1d
    Low Dose Epcoritamab Plus GemOx in R/R DLBCL (clinicaltrials.gov)
    P2, N=10, Recruiting, Hospital Universitario Dr. Jose E. Gonzalez
    New P2 trial
    |
    gemcitabine • oxaliplatin • Epkinly (epcoritamab-bysp)
    1d
    A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Recruiting --> Active, not recruiting | N=84 --> 40 | Trial primary completion date: Jun 2026 --> Jan 2026
    Enrollment closed • Enrollment change • Trial primary completion date
    2d
    Polymorphisms and overexpression of immune checkpoints PD-1, PD-L1, and CTLA-4 in DLBCL: biomarker insights from a case-control study. (PubMed, Clin Transl Oncol)
    These results suggest that overexpression of these checkpoints and related genetic variants may contribute to immune escape and disease progression in DLBCL. PD-1, PD-L1, and CTLA-4 may serve as potential biomarkers for prognosis and personalized therapy. Further large-scale studies are needed to confirm these findings.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule)